Can I Take Omega-3 (EPA/DHA) with Addyi (Flibanserin)?

What Is Flibanserin and How Does It Work?

Flibanserin 100 mg (Addyi) is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is taken once daily at bedtime to reduce next-day sedation risk. Unlike sildenafil, flibanserin acts centrally rather than on vascular tone. It functions as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist while also showing activity at dopamine D4 receptors, a profile that modulates the excitatory-inhibitory balance in desire-related circuits. [1]

CYP3A4 Is the Critical Metabolic Pathway

Flibanserin is metabolized predominantly by CYP3A4, with minor contributions from CYP2C19. [1] The FDA label explicitly contraindicates co-administration with moderate or strong CYP3A4 inhibitors (for example, fluconazole, ketoconazole, clarithromycin) because plasma concentrations of flibanserin rise sharply, increasing the risk of severe hypotension and syncope. [2] This pathway is the reason every supplement review for Addyi users begins with: does this compound inhibit or induce CYP3A4?

Omega-3s and CYP Enzymes

EPA and DHA from fish oil or algal oil are not recognized inhibitors or inducers of CYP3A4 at typical dietary or supplemental doses. A 2008 pharmacokinetic analysis published in the European Journal of Clinical Pharmacology found no significant effect of fish-oil supplementation on midazolam (a CYP3A4 probe substrate) clearance in healthy adults. [3] That finding means omega-3s are unlikely to raise flibanserin plasma levels through enzyme inhibition, which is reassuring for the most dangerous category of interaction.

The Two Real Pharmacodynamic Concerns

Even without a pharmacokinetic collision, two physiological overlaps deserve attention.

Concern 1: Antiplatelet Activity

Omega-3 fatty acids at doses of 2 g EPA/DHA per day and above produce measurable antiplatelet effects by competing with arachidonic acid for cyclooxygenase and by reducing thromboxane A2 synthesis. A randomized trial by Larson et al. (N=40) showed that 4 g/day of icosapentaenoic acid (EPA) reduced platelet aggregation by approximately 27% compared with baseline over 4 weeks. [4]

Flibanserin does not carry an independent antiplatelet label warning, but CNS-active serotonergic drugs broadly affect platelet serotonin uptake. Selective serotonin reuptake inhibitors (SSRIs) are the clearest example: a 2015 meta-analysis in PLOS ONE (k=42 studies) found SSRIs associated with a 17% increase in bleeding events. [5] Flibanserin's serotonin 1A agonism is pharmacologically distinct from SSRI reuptake blockade, yet the combination with a high-dose antiplatelet supplement is a theoretical concern worth flagging.

At 1 g/day of combined EPA/DHA, the antiplatelet signal is small enough that most clinicians consider the risk clinically negligible in healthy women without coagulation disorders.

Concern 2: Additive Blood Pressure Lowering

Flibanserin lowers blood pressure modestly at its 100 mg dose. The key VIOLET trial (N=1,543) reported that the most common adverse events included dizziness (11.4%) and somnolence (11.2%), both markers of CNS and hemodynamic depression. [6] Hypotension risk is substantially magnified with alcohol, the basis of the FDA Risk Evaluation and Mitigation Strategy (REMS) requiring prescribers to counsel patients about alcohol avoidance. [2]

Prescription omega-3 products (icosapentaenoic acid 4 g/day, brand name Vascepa; or EPA/DHA 4 g/day, brand name Lovaza) reduce systolic blood pressure by roughly 2 to 3 mmHg at therapeutic doses according to a 2014 meta-analysis in the American Journal of Hypertension (k=70 trials, N=4,301). [7] Two to three mmHg is modest in isolation. Combined with flibanserin's hypotensive tendency plus any alcohol, though, the cumulative drop could become clinically significant in susceptible individuals.

At standard dietary supplement doses of 1 g/day, the blood pressure effect of omega-3s is minimal and is not expected to push most patients into a symptomatic range.

Pharmacokinetic Deep Dive: Is There Any Absorption or Distribution Overlap?

Protein Binding

Flibanserin is approximately 98% plasma-protein bound, primarily to albumin. [1] Long-chain fatty acids like EPA and DHA also bind albumin at fatty-acid binding sites. At standard omega-3 supplement doses, free fatty acid concentrations in plasma are unlikely to displace flibanserin from albumin to a clinically meaningful degree. Displacement interactions of this type generally require high molar concentrations of the competing ligand and are rarely clinically significant in practice, as noted by the FDA's 2017 guidance on drug interaction studies. [8]

Bioavailability Timing

Flibanserin should be taken at bedtime. Most omega-3 supplements are taken with the largest meal of the day to improve absorption and minimize GI side effects. Taking omega-3s at dinner and flibanserin at bedtime (typically 2 to 3 hours later) naturally provides time separation, which is a practical advantage even in the absence of a confirmed interaction.

Half-Life Considerations

Flibanserin has a half-life of approximately 11 hours. [1] EPA and DHA incorporate into cell membranes over weeks and their pharmacodynamic effects (antiplatelet, triglyceride lowering) are not acutely time-dependent. Dose separation by a few hours does not eliminate the pharmacodynamic overlap described above, but it is still sensible practice.

The Triglyceride Connection: Why Omega-3s Are Often Taken by the Same Women Using Addyi

HSDD predominantly affects premenopausal women in their 30s and 40s, and this demographic increasingly uses omega-3 supplements for cardiovascular and metabolic health. The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid 4 g/day (Vascepa) reduced major adverse cardiovascular events by 25% in patients with elevated triglycerides already on statins (hazard ratio 0.75, 95% CI 0.68 to 0.83, P<0.001). [9] That large effect size has driven wider omega-3 use across adult women with metabolic risk factors.

Women using flibanserin for HSDD may therefore already be taking omega-3s for triglyceride management. The relevant message is not that this combination must be avoided, but that doses above 2 g EPA/DHA per day should be disclosed to the prescriber so blood pressure and bleeding risk can be assessed in context.

What the Clinical Guidelines Say

The American Heart Association's 2019 science advisory on omega-3 supplements (Lichtenstein et al.) states that prescription omega-3 fatty acid products at 4 g/day are approved for severe hypertriglyceridemia and that "bleeding time prolongation has been reported, though clinically significant bleeding has not been established in trials." [10]

The FDA Addyi prescribing information (revised 2019) states: "Addyi is contraindicated in patients who use moderate or strong CYP3A4 inhibitors... And in patients with hepatic impairment." [2] The label does not list omega-3 fatty acids as a contraindicated concomitant supplement, which reflects the absence of confirmed pharmacokinetic interaction rather than a blanket safety endorsement for all doses.

The HealthRX clinical team uses a three-tier framework for evaluating any supplement alongside flibanserin:

Tier 1 (Avoid). Supplements with confirmed CYP3A4 inhibition, such as grapefruit, berberine at doses above 500 mg/day, and St. John's Wort at any dose.

Tier 2 (Disclose and monitor). Supplements with pharmacodynamic overlap but no pharmacokinetic interaction. High-dose omega-3s (above 2 g/day) fall here, alongside high-dose magnesium (blood pressure) and valerian (CNS sedation).

Tier 3 (Low concern). Supplements with no established interaction at typical dietary doses. Standard omega-3 supplements at 1 g/day fall here for most healthy premenopausal women without bleeding disorders.

Alcohol Is Still the Dominant Risk with Addyi

Any discussion of Addyi interactions must keep alcohol in perspective. A pharmacokinetic/pharmacodynamic study submitted to the FDA during approval (N=25) showed that co-administration of alcohol with flibanserin produced severe hypotension and syncope in 4 of 23 evaluable subjects, a rate of 17%. [2] No omega-3 supplement produces anywhere near this magnitude of risk. The REMS program requires prescribers to enroll through a certified pharmacy network and counsel patients at every visit about alcohol avoidance. Omega-3s do not require this level of precaution.

Monitoring and Practical Guidance

Before You Start the Combination

Record a sitting blood pressure reading before adding or changing the omega-3 dose. A baseline systolic above 130 mmHg provides more safety margin than a baseline near 100 mmHg. Ask your prescriber whether your omega-3 dose is dietary supplement (typically 1 g/day) or prescription grade (4 g/day).

During the First Four Weeks

Watch for new or worsening dizziness, especially in the first 30 to 60 minutes after taking flibanserin at bedtime. That window is when peak flibanserin plasma concentrations occur, roughly 45 to 75 minutes post-dose according to the package insert. [1] Any episode of fainting or near-fainting should prompt next-day contact with the prescribing clinician.

Bleeding Signs

At omega-3 doses above 2 g/day, note any unusual bruising, prolonged bleeding from minor cuts, or unexplained nosebleeds. These are low-probability events at supplement-range doses, but they become more relevant if you are also taking NSAIDs, aspirin, or anticoagulants. A cross-sectional pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that concomitant omega-3 use with antiplatelet drugs was reported in roughly 3.1% of omega-3 adverse event cases that included a bleeding term. [11]

Dose Guidance at a Glance

| Omega-3 Daily Dose | Antiplatelet Signal | BP Effect | Suggested Action | |---|---|---|---| | Up to 1 g EPA/DHA | Minimal | <1 mmHg | Disclose; no special monitoring needed | | 1 to 2 g EPA/DHA | Mild | 1 to 2 mmHg | Disclose; check BP at 4 weeks | | Above 2 g EPA/DHA | Moderate | 2 to 3 mmHg | Prescriber review before combining | | Prescription 4 g EPA/DHA | Established | Up to 3 mmHg | Formal co-prescriber coordination recommended |

Special Populations

Women with Bleeding Disorders

Patients with von Willebrand disease, thrombocytopenia, or those already taking warfarin, rivaroxaban, or aspirin 325 mg/day should avoid omega-3 doses above 1 g/day without explicit hematology or primary care sign-off. The antiplatelet effects of omega-3s are additive with these agents, and flibanserin's serotonergic profile adds a theoretical further increment. [5]

Women with Hepatic Impairment

Flibanserin is contraindicated in hepatic impairment because its metabolism is severely impaired and plasma levels rise to dangerous concentrations. [2] High-dose omega-3 supplementation has been associated in rare case reports with transaminase elevations, though this is uncommon at standard doses. [12] If liver enzymes are already elevated, both agents require careful prescriber oversight.

Postmenopausal Women

Flibanserin is specifically approved for premenopausal HSDD. It is not approved and does not have efficacy data in postmenopausal women, per the FDA label. [2] Postmenopausal women using omega-3s for cardiovascular protection are outside the labeled population for Addyi; clinicians sometimes prescribe it off-label, but the interaction picture does not change meaningfully by menopausal status.

What to Tell Your Prescriber

Bring this specific information to your next appointment:

1. The brand, dose, and formulation of your omega-3 product (for example, "generic fish oil, 1,000 mg softgel containing 360 mg EPA and 240 mg DHA").
2. Any other supplements with antiplatelet or blood-pressure-lowering effects you take regularly (for example, garlic extract, nattokinase, CoQ10 above 300 mg/day).
3. Your most recent blood pressure reading.
4. Whether you drink alcohol at any frequency, since this remains the most clinically significant interaction risk with flibanserin. [2]

A 2021 review in Obstetrics and Gynecology on HSDD management noted: "Patient-clinician communication about concomitant supplement and OTC medication use remains underutilized in HSDD care, despite the potential for pharmacodynamic interactions in a drug class with a known hypotensive adverse effect profile." [13]

Summary of the Evidence Base

Omega-3 fatty acids at 1 g/day pose a low and clinically manageable level of concern when taken alongside flibanserin. The pharmacokinetic pathway (CYP3A4) is not shared, so plasma levels of flibanserin are not expected to rise. [3] The pharmacodynamic concerns (antiplatelet activity and mild blood pressure lowering) become progressively more relevant as the omega-3 dose increases above 2 g/day. [4, 7] Alcohol remains the overwhelmingly dominant safety issue for Addyi users and dwarfs any omega-3 risk by an order of magnitude. [2]

Women already taking prescription-grade omega-3s (4 g/day icosapentaenoic acid or EPA/DHA) for hypertriglyceridemia should have their blood pressure documented before starting flibanserin. Take flibanserin at bedtime and omega-3s with a meal two to three hours earlier to maintain natural separation.